Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chemosensitization by antisense oligonucleotides targeting MDM2.

Roberto Bianco1, Fortunato Ciardiello, Giampaolo Tortora

  • 1Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Università di Napoli Federico II, Via S. Pansini 5, 80131 Naples, Italy.

Current Cancer Drug Targets
|February 22, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RETRACTED: Zito Marino et al. AXL and MET Tyrosine Kinase Receptors Co-Expression as a Potential Therapeutic Target in Malignant Pleural Mesothelioma. <i>J. Pers. Med.</i> 2022, <i>12</i>, 1993.

Journal of personalized medicine·2026
Same author

Is Airway Stent a Definitive Treatment for Management of Malignant Central Airway Obstruction?

Annals of thoracic surgery short reports·2026
Same author

Clinical activity and safety of nivolumab in combination with ipilimumab in metastatic melanoma: findings from REALIPINIVO, a real-world study.

Frontiers in immunology·2026
Same author

Cancer in migrant populations: evidence from a regional oncology network.

BMC public health·2026
Same author

Proof-of-concept study of clinical use of blood-based MAVS biosensor in predicting immunotherapy response in SCLC patients.

Translational oncology·2026
Same author

Pembrolizumab for high TMB castration-resistant prostate cancer: A precision medicine case report.

International cancer conference journal·2026

Targeting the MDM2 oncogene with antisense oligonucleotides shows promise for cancer therapy. These inhibitors demonstrate antitumor activity and enhance chemotherapy and radiation efficacy, regardless of p53 status.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • The MDM2 oncogene is frequently overexpressed in various human cancers.
  • The p53-MDM2 interaction is a validated target for novel cancer therapies.
  • Current strategies include small molecules, antisense oligonucleotides, and natural agents.

Purpose of the Study:

  • To evaluate the efficacy of anti-MDM2 antisense oligonucleotides as anticancer agents.
  • To investigate the role of MDM2 inhibition in potentiating conventional cancer treatments.
  • To explore the potential of MDM2 inhibitors in combination therapies.

Main Methods:

  • Testing different generations of anti-human-MDM2 oligonucleotides in vitro and in vivo cancer models.
  • Assessing the effects of MDM2 inhibition on tumor growth, p53 activation, and chemosensitization.

Related Experiment Videos

  • Evaluating the combination of MDM2 inhibitors with chemotherapy, radiation, and EGFR inhibitors.

    • Main Results:

    • Anti-MDM2 oligonucleotides specifically inhibit MDM2 expression and exhibit significant antitumor activity.
    • Oligonucleotides potentiate growth inhibition and p53 activation by chemotherapeutic agents.
    • MDM2 inhibitors act as chemosensitizers and radiosensitizers, irrespective of p53 status.
    • Combination with EGFR inhibitors enhances anti-proliferative and pro-apoptotic effects in prostate cancer cells.

    Conclusions:

    • Anti-MDM2 antisense oligonucleotides represent a promising new class of anticancer agents.
    • MDM2 inhibitors can enhance the effectiveness of conventional therapies like chemotherapy and radiation.
    • Integrating MDM2 inhibitors with other treatments offers novel therapeutic strategies for various cancers.